In this podcast, Prof Thorsten Zenz from University Hospital in Zurich, Switzerland, discusses the current approaches to treatment of relapsed hairy cell leukemia (HCL). Based on his personal journey as a hematologist interested in precision oncology, prof. Zenz summarizes the years of accumulating data and clinical experience to explain the treatment approach he often uses for his patients.

Thanks to the clear molecular target (V600E mutation of BRAF), treatment of classical hairy cell leukemia with BRAF inhibitors, such as vemurafenib, is an example of precision oncology that can result in deep responses. As combination of this treatment with anti-CD20 antibody leads to durable complete responses in most patients, Prof Zenz often uses this regime in his patients with refractory or relapsed hairy cell leukemia.

However, as different countries have access to different treatment options, Prof Zenz also discusses the role, sequencing and combinations of other drugs, such as to purine analogs (i.e. cladribine), MEK inhibitors, BTK-inhibitors, Bcl-2 inhibitors (i.e. venetoclax) or recombinant CD22-targeting immunotoxin (i.e. moxetumomab). In light of emerging (although still limited) data on these drugs and questions about their optimal sequencing, guidelines are being developed by Hairy Cell Leukemia Foundation (HCLF) and EHA that aim to help the clinicians with making choices for their patients.

This podcast is further enriched by insights from prof. Enrico Tiacci from University and Hospital of Perugia in Italy, who discovered that V600E mutation of BRAF is the key genetic lesion underlying hairy cell leukemia. Prof Tiacci shares his views on the treatment options and their sequencing, based on the clinical trials he conducted and his clinical experience.

Guest: Prof Thorsten Zenz

This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned!

For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

In this episode of EHA Unplugged, Prof Kirsten Grønbæk and our guests Prof Yelena Ginzburg and Prof Amit Verma discuss iron metabolism and its role in erythropoiesis in MDS.

The experts share their views on the management of iron overload in the transfusion-dependent patients with MDS, as they acknowledge that it poses a real challenge in their clinical practice. Starting from the criteria used to select patients for iron chelation and then discussing its beneficial effects and limitations, the podcast guests formulate clear thoughts on the role of this therapy in both low- and high-risk MDS. They then clarify recent scientific insights into the putative mechanisms that may link iron overload with the ineffective erythropoiesis.

Please tune in to hear about the data from a mouse model pointing to the role of iron transport in erythroblast function and differentiation (please also see the Reference). You will also hear what direction the future research into the mechanism of the communication between ineffective erythropoiesis and iron metabolism may take.

Host: Prof Kirsten Grønbæk

University of Copenhagen, Denmark

Guests:

Prof Yelena Ginzburg

Icahn School of Medicine at Mount Sinai, NY, USA

Prof Amit Verma

Albert Einstein College of Medicine, NY, USA

Reference: An W, et al. Iron chelation improves ineffective erythropoiesis and iron overload in myelodysplastic syndrome mice. Elife. 2023 Dec 28:12:e83103. doi: 10.7554/eLife.83103 

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

In this podcast, Dr Elisabeth Schorb from University Medical Center in Freiburg, Germany, discusses the first-line treatment of primary central nervous system lymphoma (PCNSL), which has seen tremendous advances in the last years. PCNSL is a rare condition, and because of its location prompt diagnosis and timely treatment are of the essence.

As for other hematological diseases, treatment of PCNSL today is based on two pillars: induction treatment and consolidation treatment. Listen to Dr Schrob describe her clinical experience and contributions to the international clinical trials that have shifted PCNSL prognosis from a disease with short life-expectancy if left untreated to a curable disease. And get inspired by Dr Schorb’s appeal to “stay tuned, stay in touch because your investigator-initiated ideas can make all the difference”. 

Guest: Dr Elisabeth Schorb

This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned!

For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

With the increasing scrutiny of healthcare pathways for women, this podcast provides a timely plea by Dr Michelle Lavin from St. James’s Hospital in Dublin, Ireland, to optimize global care for women with von Willebrand disease (VWD).

In this podcast, Dr Lavin gives a passionate appeal for more international collaboration and increased awareness to improve care for women and girls suffering from bleeding disorders. As challenges facing women with these disorders are multiple, including diagnostic inequalities and suboptimal treatments, the solutions are also multi-factorial. Listen to dr. Lavin give her recommendations to provide the best possible care, based on the findings from the Annual Global Survey of the World Federation of Hemophilia, World Bleeding Disorder Registry and other data.

In Dr Lavin’s own words: “there's momentum behind Women's Health”, so tune in to participate. 

Guest: Dr Michelle Lavin

This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned!

For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

In this lecture from EHA2024, Prof Domenico Girelli from University of Verona, Italy, discusses the complex relationship between iron metabolism and infection.

As an essential element for physiology of all living organisms, iron is involved in many vital processes, including our immune responses to infections. Since the pathogens themselves also depend on iron to survive, the resulting host/pathogen “battle” for iron is one of the key determinants of outcomes of most infectious diseases.

Interestingly, this dependence of pathogens on iron may offer a much-needed solution for multidrug resistance (MDR) of microbes, which poses a significant and growing challenge for the global healthcare. Tune in, to hear about the novel “metallo-antibiotics” and other clinical developments based on accumulating data about role of iron in infections. 

Guest: Prof Domenico Girelli

This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned!

For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for an insightful lecture by Prof Maria Teresa Voso from University of Rome Tor Vergata in Italy, as she discusses the advances in the treatment of a rare subtype of AML, the acute promyelocytic leukemia (APL). As the PML::RARA rearrangement, resulting in a fusion protein that disrupts retinoic acid signaling and PML function, is the hallmark driver of APL, it is used as target for APL treatment.

Listen to Prof Voso as she talks about the scientific developments leading to significant improvements in clinical outcomes for patients with APL and the role of ATRA / ATO therapy, which combines all-trans retinoic acid (ATRA) and arsenic trioxide (ATO).

Prof Voso highlights contributions of the late prof. Francesco Lo Coco, the significance of the EU-wide HARMONY registry and other collaborative efforts in establishing the optimal treatment regimens for APL. This podcast also provides insights into remaining open issues in the clinical management of APL, including high-risk APL for which the results of the much-anticipated APOLLO trial may provide some answers. 

This is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. The podcasts in this series are better consumed in video form because of the accompanying slide content. More lectures will be available in the future. Stay tuned!

For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/

Guest: Prof Maria Teresa Voso

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this engaging debate on the future of acquired TTP (aTTP) treatment chaired by Dr. Eleni Gavriilaki from Aristotle University of Thessaloniki in Greece. This discussion features Prof. Marie Scully from University College London Hospital in UK and Prof. Paul Coppo from Saint-Antoine Hospital in Paris, France. The debate centers on whether therapeutic plasma exchange (PEX) combined with immunosuppression, long considered the standard treatment for acute aTTP episodes, has become obsolete with the advent of new therapies.  

First Prof. Scully argues that plasmapheresis is indeed a thing of the past, citing its complexity and inherent safety concerns. Prof Scully predicts that the best alternative option will incorporate the use of recombinant ADAMTS13, caplacizumab and immunosuppression primarily with steroids and anti-CD-20 therapy. 

In contrast, Prof Coppo argues that a PEX-free strategy cannot be universally applied to all aTTP patients, regardless of clinical presentation and severity because there is insufficient data yet to support this approach, the availability of caplacizumab is not guaranteed. 

Tune in for this debate to hear further our experts’ views on the impact of treatment costs on availability and clinical decision making.  

Guests:

Dr Eleni Gavriilaki 

Aristotle University of Thessaloniki, Greece 

Prof Marie Scully

University College London, UCLH, London, UK 

Prof Paul Coppo

Sorbonne University and Saint-Antoine Hospital, Paris, France 

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us in this podcast episode to get a glimpse of what the future holds in the big field of innovation in hematology. With the help of our host, Dr Gregor Hormann (MLL Munich Leukemia Laboratory, Germany), you will be taken on a journey toward a future that is already here.   

Dr Hormann will discuss the many potentials of AI in hematology and oncology, including the automated integrated diagnostic tools, from morphology to chromosomal banding analysis in a few minutes, new classification algorithms, and innovative large language models (LLMs) assisting physicians in the diagnosis prediction.  

The take-home message? "AI will not replace physicians. However, physicians who use AI will replace those who don't." 

Host: Dr Wilson Lim

Guest: Dr Gregor Hormann

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Tune in to EHA Unplugged for an engaging chat with Professor Lars Bullinger from Charité University Medicine, Berlin. He'll break down the latest in myeloid disease classification, discussing how new genetic insights are transforming our understanding of MDS and AML.

Discover the hurdles clinicians face, the promise of innovative treatments, and the future of preventive medicine, including the impact of clonal hematopoiesis and cutting-edge sequencing tech.  

Host: Prof Kirsten Grønbæk

Guest: Professor Lars Bullinger

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for an insightful episode featuring Prof David Rees from King’s College Hospital in London as he discusses screening practices for Sickle Cell disease (SCD). Hosted by Dr Sarah de Vlieger, this discussion explores both antenatal and neonatal screening practices for Sickle Cell disease.

The conversation begins with an examination of antenatal screening challenges, comparing various techniques such as carrier screening, amniocentesis, chorionic villus sampling, and emerging non-invasive prenatal testing. Prof Rees and Dr de Vlieger then address the complex decisions arising from these test results and the disparities in screening access across different countries and cultures.

Moving to neonatal screening, Prof Rees emphasizes its crucial role in implementing early preventive measures. He advocates for the inclusion of Sickle Cell testing in general neonatal screening programs throughout Europe and aspires for screening to become more accessible in regions with higher disease prevalence.

Host: Sarah de Vlieger, EHA Head of Education

Guest: Prof David Rees

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe